Multiple sclerosis is a neurological condition in which the immune system mistakenly attacks myelin, the protective covering around nerve fibers in the central nervous system. This immune activity can cause inflammation and interfere with communication between the brain, spinal cord, and the rest of the body. Ocrevus, also known by its generic name ocrelizumab, is designed to target a particular type of immune cell called a B cell. It is used for adults with relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
Ocrevus is a monoclonal antibody that targets CD20, a protein found on certain B cells. B cells are part of the immune system and can contribute to the inflammatory processes associated with multiple sclerosis. By binding to CD20, Ocrevus helps reduce these B cells from circulation. This changes part of the immune response involved in multiple sclerosis activity.
The medication does not remove every B cell from the body, and its effects are not the same as general immune suppression. Instead, it focuses on a particular population of B cells. The reduction of these cells can decrease inflammatory activity that may contribute to damage in the central nervous system.
Key aspects of how Ocrevus works include:
Ocrevus is administered through intravenous infusion under the supervision of healthcare professionals. The initial treatment is divided into two infusions, while subsequent treatments are generally given at regular intervals. Before and during treatment, healthcare professionals may evaluate a person's medical history, current health, and potential risks.
Because Ocrevus affects specific immune cells, monitoring is an important part of treatment. Infusion-related reactions can occur, and healthcare professionals may observe patients during and after administration. Infections are another consideration because changes in immune function can influence the body's ability to respond to certain infections.
Important considerations may include:
Ocrevus does not cure multiple sclerosis, and treatment decisions depend on the individual's type of multiple sclerosis, symptoms, medical history, and other factors. Healthcare professionals determine whether this medicine is appropriate and how treatment should be monitored.
Ocrevus works by targeting CD20 positive B cells that contribute to immune activity associated with multiple sclerosis. Its role is to reduce certain immune cells and help control disease activity in relapsing multiple sclerosis and primary progressive multiple sclerosis. Understanding its mechanism, administration, and monitoring requirements can provide useful background for people learning about multiple sclerosis treatment. This information is for educational purposes only and is not a substitute for advice from a qualified healthcare professional.